From April 12 to 14, more than 200 people from around the world gathered in San Antonio, TX, for the first-ever RetreatMigraine conference. Produced by CHAMP (the Coalition for Headache And Migraine Patients) the three-day educational event aimed to connect those with migraine disease with information, resources, and most importantly, each other.
A member organization of CHAMP, U.S. Pain Foundation sponsored a dinner and launch party for its latest issue of the INvisible Project. The magazine–the third edition focusing on headache diseases–includes profiles of 10 inspiring individuals who are living with migraine, headache, and cluster diseases. The launch party featured large displays with photos, story summaries, and quotes from each person profiled.
It’s National Migraine and Headache Awareness Month (MHAM), and we have a number of exciting developments to kick it off, as well as numerous ways to participate. Be sure to follow U.S. Pain on Facebook and Twitter to stay up to date on the latest news, events, and ways to get involved.
First-ever migraine prevention drug approved
On May 17, the Food and Drug Administration (FDA) approved the first-ever migraine preventive drug. Often referred to as a CGRP (calcitonin gene-related peptide) or CGRP inhibitor, the drug blocks the CGRP receptor that is believed to play a role in migraine.